Inhibition of protein synthesis: a mechanism of amebicide action of emetine and other structurally related compounds.
N Entner, A P Grollman
https://pubmed.ncbi.nlm.nih.gov/4347870/Actively Recruiting
Led by Johns Hopkins University · Updated on 2026-10-13
600
Participants Needed
2
Research Sites
9 weeks
Total Duration
Researchers are evaluating the effects of oral emetine in patients aged 18 to 65 years who have symptomatic dengue fever. This study aims to determine whether emetine can reduce 28-day mortality or progression to severe dengue, including severe plasma leakage, bleeding, or organ involvement. It also assesses the safety of emetine, including serious side effects and toxicities. Dengue fever is a significant global health concern transmitted by mosquitoes, with no proven antiviral treatment currently available, and this study explores emetines potential as an antiviral agent. Participants will receive one of three treatments 6 mg emetine, 12 mg emetine, or a placebo pill taken orally for 10 consecutive days. The study is randomized, double-blinded, and placebo-controlled, ensuring unbiased assessment across groups. Blood samples will be collected for at least five days to monitor viral load, inflammatory markers, and safety parameters. The research builds on previous studies indicating emetines antiviral activity at low doses without significant cardiovascular toxicity. During the study, participants will be monitored daily by healthcare staff who will record vital signs and symptoms for clinical assessments over 28 days. Blood tests will measure changes in viral load and various inflammatory markers, while questionnaires will assess fatigue after infection on day 28. The primary outcomes focus on mortality, disease progression, and safety events within 28 days. Participants will be closely followed to track recovery time, viral clearance, and any adverse reactions throughout the trial.
CONDITIONS
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
K
Kunchok Dorjee, MBBS, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johns Hopkins University
Lead Sponsor
Bharatpur Hospital Chitwan
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Emetine 6 mg | Emetine 12 mg | Placebo | Supportive Care (current practice) |
|---|---|---|---|---|
| What it is | Oral emetine hydrochloride 6 mg once daily for symptomatic dengue patients | Oral emetine hydrochloride 12 mg once daily for symptomatic dengue patients | Oral placebo once daily for the same duration | Supportive clinical management without antiviral drug |
| Primary use | Test whether 6 mg emetine reduces mortality or progression compared to placebo | Test whether 12 mg emetine reduces mortality or progression compared to placebo | Serve as control for comparison on mortality or progression | Manage dengue patients with hydration, symptom control, and monitoring |
| Evidence status | Efficacy is under evaluation; no published human results yet | Efficacy is under evaluation; no published human results yet | Control arm; serves as baseline for assessing investigational drug | Supportive care is the current standard but has not shown antiviral efficacy |
| Important limitations | Safety and optimal dosing in dengue patients are not yet established | Safety and optimal dosing in dengue patients are not yet established | Placebo provides no therapeutic benefit and does not reflect usual care | Supportive care does not include antiviral action against dengue virus |
| Patient impact | Unknown; trial results pending | Unknown; trial results pending | Placebo has no therapeutic effect; patient outcomes reflect disease natural course | Supportive care may reduce risk of severe complications through hydration and monitoring |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 10 days
Participants take either 6 mg emetine, 12 mg emetine, or placebo pills orally once daily for 10 consecutive days.
Daily visits for clinical assessment and monitoring
Duration - 28 days
Participants are monitored daily for 28 days for vital signs, symptoms, and safety assessments including blood tests.
Daily monitoring visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
N Entner, A P Grollman
https://pubmed.ncbi.nlm.nih.gov/4347870/A P Grollman
https://pubmed.ncbi.nlm.nih.gov/16591432/C S Bhat, R Shetty, Balasubramanian Sundaram...
https://pubmed.ncbi.nlm.nih.gov/35680407/Ka-Tim Choy, Alvina Yin-Lam Wong, Prathanporn Kaewpreedee...
https://pubmed.ncbi.nlm.nih.gov/32251767/Martin D Bleasel, Gregory M Peterson
https://pubmed.ncbi.nlm.nih.gov/33261173/Hemalatha Beesetti, Navin Khanna, Sathyamangalam Swaminathan
https://pubmed.ncbi.nlm.nih.gov/27322111/Maria G Guzman, Duane J Gubler, Alienys Izquierdo...
https://pubmed.ncbi.nlm.nih.gov/27534439/Eng Eong Ooi
https://pubmed.ncbi.nlm.nih.gov/33124646/Johns Hopkins University
Lead Sponsor
Bharatpur Hospital Chitwan
Collaborating Sponsor